Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,579.90 | 50.10 | 0.59% |
| CAC 40 | 7,886.69 | 33.22 | 0.42% |
| DAX 40 | 23,767.43 | 71.84 | 0.30% |
| Dow JONES (US) | 42,654.74 | 331.99 | 0.78% |
| FTSE 100 | 8,684.56 | 50.81 | 0.59% |
| HKSE | 23,345.05 | 108.11 | -0.46% |
| NASDAQ | 19,211.10 | 98.78 | 0.52% |
| Nikkei 225 | 37,753.72 | 1.79 | -0.00% |
| NZX 50 Index | 12,786.79 | 94.03 | -0.73% |
| S&P 500 | 5,958.38 | 41.45 | 0.70% |
| S&P/ASX 200 | 8,343.70 | 46.20 | 0.56% |
| SSE Composite Index | 3,367.46 | 13.36 | -0.40% |